The 2:17 A.M. Test: 7 Things Every Biotech CISO Should Prove About Threat Monitoring
Your biotech does not have 24/7 threat monitoring simply because your security technology operates 24/7.
That may sound obvious.
Operationally, it is one of the most important distinctions a CISO can make.
Security tools do not sleep.
People do.
That creates a coverage problem for biotech companies trying to protect valuable intellectual property with lean IT and security organizations.
The real test isn’t what happens at 10:00 Tuesday morning when everyone is available.
The real test is what happens at 2:17 Sunday morning when a critical alert appears.
- Can your organization detect it?
- Can someone investigate it within minutes?
- Can someone make a decision?
- Can someone escalate it?
- Can someone contain it?
- And afterward, can leadership prove what happened?
If any of those answers are uncertain, your monitoring strategy deserves closer examination.
Proof #1: Someone Owns the Alert
Start with the simplest question:
Who owns a critical security alert at 2:17 a.m.?
Not which mailbox receives it.
Not which dashboard displays it.
Which human being becomes accountable for determining whether something malicious is happening?
This exposes weaknesses quickly.
In smaller biotech organizations, alerts may go to a shared mailbox, an IT employee’s phone, an outsourced technology provider or multiple people without clear ownership.
Everyone receives the alert.
Nobody truly owns it.
Monitoring requires accountability.
For critical events, leadership should know:
- Who receives the notification.
- Who acknowledges it.
- Who becomes responsible for investigation.
Proof #2: Response Time Is Measured
“Someone will look at it” is not a response standard.
How long can a potentially compromised account access sensitive research before somebody begins investigating?
- Five minutes?
- Thirty minutes?
- Two hours?
- The next morning?
The answer should not depend on whether somebody happens to notice the alert on their phone.
NIST’s current incident-response guidance emphasizes integrating incident response throughout cybersecurity risk management to improve the effectiveness of detection, response and recovery activities.
For security leadership, that means defining expectations before the incident.
If you use a managed security service provider, examine contractual service levels carefully.
Ask about:
- Acknowledgment time.
- Investigation time.
- When escalation occurs.
And make sure “response” does not merely mean that an automated system opened a ticket.
Proof #3: Alerts Are Investigated, Not Forwarded
This is one of the biggest distinctions between having monitoring technology and having a security operation.
Suppose the SIEM identifies unusual authentication activity.
A weak process sends your IT director an email:
Possible suspicious login detected. Please investigate.
That is alert forwarding.
It is not necessarily managed detection and response.
A meaningful investigation should help answer:
- Was the authentication legitimate?
- What user was involved?
- What device was involved?
- What occurred before the alert?
- What happened afterward?
- Was sensitive information accessed?
- Are there related indicators elsewhere?
- Does the activity require containment?
The value comes from reducing uncertainty while time still matters.
Proof #4: The Analyst Has Enough Context
Your biotech network does not exist in isolation.
Research systems matter differently from conference-room equipment.
A privileged identity carries different risk than a standard account.
Access to proprietary data creates different consequences than access to a public marketing site.
Security monitoring becomes dramatically more useful when analysts understand what matters to the business.
This is why context should be part of any managed-security evaluation.
Ask:
- Can the monitoring team identify critical systems?
- Do they understand escalation paths?
- Do they know which users or assets deserve immediate attention?
- Do documented runbooks reflect your environment?
If the external security team treats every alert exactly the same, you may have monitoring capacity without enough business context.
Proof #5: Escalation Does Not Depend on One Employee
One of the easiest ways to expose a fragile security model is to remove one person from it.
Imagine your senior IT administrator is unavailable for 48 hours.
Does the process still work?
Too many smaller organizations build security processes around institutional knowledge held by individuals.
- “Call Steve.”
- “Tom normally handles that.”
- “The CISO gets those alerts.”
That can work until that person is unavailable during the incident that matters.
Real operational maturity requires documented escalation.
- Primary contact.
- Secondary contact.
- Severity criteria.
- Communication methods.
- Authority.
- Containment expectations.
The process should survive vacations, illness and employee turnover.
Proof #6: The Organization Can Show What Happened
Executives should care about evidence.
If an incident occurs, leadership will eventually ask questions such as:
- When did we first detect it?
- When did someone investigate?
- What systems were affected?
- What information may have been accessed?
- When did we contain the activity?
- What decisions were made?
CISA stresses the importance of event logging because logs can support intrusion detection, mitigation and understanding the extent of an incident.
That record becomes especially important when intellectual property is involved.
Biotechnology companies can carry enormous value in nonphysical assets: research knowledge, proprietary processes, molecular information, manufacturing information and trade secrets.
The JHL Biotech case involving Genentech trade secrets demonstrated just how consequential intellectual-property disputes can become. DOJ reported both criminal convictions and losses associated with a scheme involving confidential biopharmaceutical information. The matter was not a traditional cybersecurity breach, but it provides an important business lesson: protecting proprietary information is inseparable from protecting enterprise value.
Proof #7: Coverage Continues After Employees Go Home
This is the test many organizations avoid.
Security technology is easy to run around the clock.
Security people are expensive to staff around the clock.
Creating genuine 24/7 coverage internally can require:
- Multiple analysts.
- Scheduling coverage.
- Management.
- Processes.
- Training.
- Backup staffing.
- The ability to maintain operations when employees leave.
For many biotech companies under $500 million in revenue, building that capability internally may compete with dozens of other business priorities.
That does not mean leadership should accept an overnight security gap.
It means the operating model may need to change.
Managed security can give internal IT and security teams access to dedicated monitoring personnel, broader security experience, structured escalation and after-hours coverage without requiring the biotech to recreate an entire security operations center internally.
The key is choosing the provider correctly.
Do not select one simply because it claims “24/7 monitoring.”
Ask them to prove it.
What to Ask a Managed Security Provider
Before making a decision, ask:
- Who monitors our environment overnight?
- What qualifications do those analysts have?
- What constitutes a critical incident?
- How quickly is a critical alert acknowledged?
- How quickly does investigation begin?
- Are response expectations contractual?
- What investigation occurs before our internal team is contacted?
- What authority does your team have?
- How are incidents escalated?
- What evidence and reporting will we receive?
- How will you learn which systems matter most to our company?
- What happens if our primary internal contact cannot be reached?
Those questions tell you much more than another product demonstration.
The Question Leadership Should Be Asking
The goal is not to replace your internal IT or security organization.
The goal is to stop asking a small internal team to provide an operating capability it was never staffed to provide.
Managed security should be evaluated as additional security capacity: qualified people, documented processes, defined service levels and continuous coverage surrounding the tools you already own.
But don’t assume you need it.
Prove it.
Take one critical threat scenario and walk it through your existing operation.
Start at 2:17 a.m.
- Follow the alert.
- Measure the acknowledgment.
- Examine the investigation.
- Test the escalation.
- Identify who can act.
- Request the evidence.
If the process works, you have something valuable.
If it falls apart because nobody is available until morning, you have discovered a security exposure before an attacker discovers it for you.
That is where a meaningful security assessment should begin.
Not with:
“Which security products should we buy?”
But with:
“Can we prove that the systems protecting our intellectual property are continuously monitored, investigated and supported by people capable of acting when something goes wrong?”
For a biotech company building value around intellectual property, research and future commercialization, that is not merely a cybersecurity question.
It is a valuation question.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
